Back to Agenda
Session 8: Regulatory Convergence in Pandemic Situations
Session Chair(s)
Roberta Mele Mazza, RPh, RAC
Q&RA Manager, División Diagnóstica
Productos Roche , Argentina
Maria Cristina Mota Pina, MBA
Director, Regulatory Policy and Intelligence -Japan, Emerging Markets, Australia
Latin America Federation of Pharmaceutical Industry (FIFARMA), United States
“Regulatory convergence,” represents a process whereby the regulatory requirements across countries or regions become more similar or “aligned” over time. This session aims to provide an overview of “lessons learned” during a pandemic situation and share examples of good regulatory practices for medical devices and medicines in the Latin America the region.
Learning Objective : - Raise the awareness on different Convergence initiatives already existing and new initiatives for medical devices and medicines
- Understand how Regulators are working towards regulatory convergence in pandemic situations for medical devices and medicines
- Provide an industry perspective in how regulatory convergence initiatives supports availability of medical devices and medicines in pandemic situations
Speaker(s)
Speaker
Agnès Saint-Raymond, DrMed
European Medicines Agency, Netherlands
Head of Division International Affairs
Regulatory Convergence in Pandemic Situations an Industry perspective
Rebecca Lumsden, PhD
Sanofi, United Kingdom
Head of Regulatory Science & Policy EU/AMEE
Regulatory Convergence in Pandemic Situations
Sandra Ligia González Aguirre
Inter-American Coalition For Regulatory Convergence, Medical Technology Sector, United States
Executive Secretary, Inter-American Coalition for Regulatory Convergence
Panelist
Steven Bipes, PhD
Advanced Medical Technology Association (AdvaMed), United States
Vice President - Global Strategy and Analysis
Have an account?